Diagnostik und Therapie der Legionellen-Pneumonie

 

 Permissions and Reprints

Zusammenfassung

Die Herausforderung in der Diagnostik der Legionellen-Pneumonie besteht darin, dass die Legionellen-Pneumonie relativ selten ist, andererseits jedoch häufiger als viele andere Erreger einen schweren Verlauf nimmt. Den wichtigsten Fortschritt in der Diagnostik der Legionellen-Pneumonie stellt der Antigennachweis im Urin durch einen immunchromatografischen Schnelltest (ICT) dar. Dieser kann bettseitig durchgeführt werden, ist einfach in der Handhabung und kann binnen 15 Minuten abgelesen werden. Die Sensitivität beträgt ca. 80 %, die Spezifität 100 %. Der Stellenwert dieses Tests innerhalb der Entscheidungsalgorithmen in der Versorgung von Patienten mit ambulant erworbener Pneumonie ist jedoch noch nicht geklärt. Mit Makroliden, Doxycyclin, Fluorchinolonen und Ketoliden, mit Einschränkung auch mit Streptograminen, stehen Substanzen mit sicher oder sehr wahrscheinlich ausreichender Wirksamkeit gegenüber Legionella spp. zur Verfügung, die somit für eine kalkulierte initiale antimikrobielle Therapie der ambulant erworbenen Pneumonie infrage kommen. In der gezielten antimikrobiellen Therapie sollten Makrolide und Fluorchinolone den Vorzug erhalten. Bei leichten bis mittelschweren Pneumonien sollten vorzugsweise neue Makrolide oral zur Anwendung kommen, innerhalb der Makrolide ergeben sich für das Azithromycin Vorteile. Alternativen sind Ciprofloxacin, Levofloxacin und Moxifloxacin. Bei schweren Legionellen-Pneumonien sowie unabhängig vom Schweregrad bei nosokomialen Legionellen-Pneumonien und solchen unter Immunsuppression stellen die genannten Flurochinolone intravenös die Therapie erster Wahl dar. Alternativ kann intravenös Azithromycin zur Anwendung kommen. Ob eine Kombinationstherapie aus Azithromycin oder Fluorchinolon und Rifampicin oder Azithromycin und Fluorchinolon einer Monotherapie überlegen ist, muss zum jetzigen Zeitpunkt offen bleiben.

Abstract

Legionellosis is a relatively rare condition but nevertheless is associated more frequently than many other pathogens with a severe course. Therefore, establishing a diagnosis of Legionellosis remains a challenge. The most significant progress in the diagnosis of Legionellosis is antigen-testing in urine by a rapid immunochromatographic test (ICT). This is an easy to handle bedside test which provides a result within 15 minutes. Sensitivity and specificity reach 80 % and 100 %, respectively. However, the exact place of this test within algorithms of clinical decision making still remains unsettled. Macrolides, doxycycline, fluoroquinolones and ketolides, and possibly also streptogramins are drugs with definitely or most probably sufficient activity against Legionella spp. and, therefore, are appropriate candidates within empirical initial antimicrobial treatment regimen of community-acquired pneumonia. Macrolides and fluoroquinolones should be the drugs of choice for the treatment of established Legionellosis. Oral macrolides should be prefered in patients with mild to moderate pneumonia; within the macrolides, azithromycin has the most favourable profile of activity. Alternatively, ciprofloxacin, levofloxacin and moxifloxacin may be selected. In severe Legionellosis as well as independently of severity in nosocomial legionellosis and immunosuppressed patients, intravenous fluoroquinolones are first choice drugs. Alternatively, azithromycin may be used. Whether a combination treatment including azithromycin or fluoroquinolones with rifampin or azithromycin with fluoroquinolone exert superior activity remains currently unknown.

Literatur

• 1 Ewig S, Torres A. Severe community-acquired pneumonia.  Clin Chest Med. 1999;  20 575-587
  CrossrefPubMedGoogle Scholar
• 2 Huchon G, Woodhead M. Management of adult community-acquired lower respiratory tract infections.  Eur Respir Rev. 1998;  8 391-426
  PubMedGoogle Scholar
• 3 Ruiz M, Ewig S, Torres A, Arancibia F, Mensa J, Martinez J M, Gonzalez J. Severe community-acquired pneumonia: risk factors and follow-up epidemiology.  Am J Respir Crit Care Med. 1999;  160 923-929
  PubMedGoogle Scholar
• 4 Korvick J, Yu V L, Fang G D. The role of Legionella spp. in nosocomial pneumonia.  Semin Respir Infect. 1987;  2 34-47
  PubMedGoogle Scholar
• 5 Chow J, Yu V L. Legionella: a major opportunistic pathogen in transplant recipients.  Smin Respir Infect. 1998;  13 132-139
  PubMedGoogle Scholar
• 6 Heath C H, Grove D I, Looke D F. Delay in appropriate therapy of Legionella pneumonia associated with increased mortality.  Eur J Clin Microbiol Infect Dis. 1996;  15 286-290
  CrossrefPubMedGoogle Scholar
• 7 Chiba Y, Okamoto H, Nagamoto A, Kunikane H, Waranabe K. Legionnaires disease diagnosed by bronchoalveolar lavage.  Intern Med. 1998;  37 153-156
  PubMedGoogle Scholar
• 8 Rihs J D, Yu V L, Zuravleff J J, Goetz A, Muder R R. Isolation of Legionella pneumophila from blood using the BACTEC: a prospective study yielding positive results.  J Clin Microbiol. 1985;  22 422-424
  PubMedGoogle Scholar
• 9 Plouffe J F, File T, Breiman R F, Hackman B A, Salstrom S, Marston S J. et al . Reevaluation of the definition of Legionnaires disease: use of the urinary antigen assay. Community based pneumonia incidence study group.  Clin Infect Dis. 1995;  20 1286-1291
  PubMedGoogle Scholar
• 10 Benson R F, Tang P W, Fields B S. Evaluation of the Binax and biotest urinary antigen kits for detection of Legionnaires' disease due to multiple serogroups and species of Legionella.  J Clin Microbiol. 2000;  38 2763-2765
  PubMedGoogle Scholar
• 11 Dominguez J A, Manterola J M, Blavia R, Sopena N, Belda F J, Padilla E, Gimenez M, Sabria M, Morera J, Ausina V. Detection of Legionella pneumophila serogroup 1 antigen in nonconcentrated urine and urine concentrated in selective ultrafiltration.  J Clin Microbiol. 1996;  34 2334-2346
  PubMedGoogle Scholar
• 12 Franzin L, Cabodi D. Comparative evaluation of two commercially available antigen enzyme immunoassays (EIA) for the detection of Legionella pneumophila urinary antigen in frozen non-concentrated urine samples.  New Microbiol. 2000;  23 383-389
  PubMedGoogle Scholar
• 13 Chang F Y, Stout J E, Yu V L. Assessment of enzyme immonassays versus radioimmunoassay for detection of Legionella pneumophila serogroup 1 antigen in frozen urine specimens.  J Clin Microbiol. 1996;  34 2628-2629
  PubMedGoogle Scholar
• 14 Hackman B A, Plouffe J F, Benson R F, Fields B S, Breiman R F. Comparison of Binax Legionella urinary antigen EIA kit with Binax RIA urinary antigen kit for detection of Legionella pneumophila serogroup 1 antigen.  J Clin Microbiol. 1996;  34 1579-1580
  PubMedGoogle Scholar
• 15 Kazandjian D, Chiew R, Gilbert G L. Rapid detection of Legionella pneumophila serogroup 1 infection with the binax enzyme immunoassay urinary antigen test.  J Clin Microbiol. 1997;  35 954-956
  PubMedGoogle Scholar
• 16 Kohler R B, Winn Jr W C, Wheat L J. Onset and duration of urinary antigen excretion in Legionnaires disease.  J Clin Microbiol. 1984;  20 605-607
  PubMedGoogle Scholar
• 17 Stout J E, Yu V L. Legionellosis.  N Engl J Med. 1997;  337 682-687
  CrossrefPubMedGoogle Scholar
• 18 Oliverio M J, Fisher M A, Vickers R M, Yu V L, Menon A. Diagnosis of Legionnaires' disease by radioimmunoassay of Legionella antigen in pleural fluid.  J Clin Microbiol. 1991;  29 2893-2894
  PubMedGoogle Scholar
• 19 Helbig J H, Uldum S A, Luck P C, Harrison T G. Detection of Legionella pneumophila antigen in urine samples by the BinaxNOW immunochromatographic assay and comparison with both Binax Legionella urinary enzyme immunoassay (EIA) and Biotest Legionella urin antigen EIA.  J Med Microbiol. 2001;  50 509-516
  PubMedGoogle Scholar
• 20 Dominguez J, Gali N, Matas L, Pedroso P, Hernandez A, Padilla E, Ausina V. Evaluation of a rapid immunochromatographic assay for the detection of Legionella antigen in urine samples.  Eur J Clin Microbiol Infect Dis. 1999;  18 896-898
  CrossrefPubMedGoogle Scholar
• 21 Wever P C, Yzerman E PF, Kuiper E J, Speelman P, Dankert J. Rapid diagnosis of Legionnaires' disease using an immunochromatographic assay for Legionella pneumophila serogroup 1 antigen in urine during an outbreak in the Netherlands.  J Clin Microbiol. 2000;  38 2738-2739
  PubMedGoogle Scholar
• 22 Ewig S. Community-acquired pneumonia. Epidemiology, risk, and prognosis.  Eur Respir Mon. 1997;  14 95-102
  PubMedGoogle Scholar
• 23 Kessler H H, Reinthaler F F, Pscaid A, Pierer K, Kleinhappl B, Eber E, Marth E. Rapid detection of Legionella species in bronchoalveolar lavage fluids with the EnviroAmp Legionella PCR amplification and detection kit.  J Clin Microbiol. 1993;  31 3325-3328
  PubMedGoogle Scholar
• 24 Matsiota-Bernard P, Pitsouni E, Lagakis N, Nauciel C. Evaluation of commercial amplification kit for the detection of Legionella pneumophila in clinical specimen.  J Clin Microbiol. 1994;  32 1503-1505
  PubMedGoogle Scholar
• 25 Maiwald M, Schill M, Stockinger C, Helbig J H, Luck P C, Witzleb W, Sonntag H G. Detection of Legionella DNA in human and guinea pig urine samples by the polymerase chain reaction.  Eur J Clin Microbiol Infect Dis. 1995;  14 25-33
  PubMedGoogle Scholar
• 26 Helbig J H, Engelstädter T, Maiwald M, Uldum S A, Witzleb W, Lück P C. Diagnostic relevance of the detection of Legionella DNA in urine samples by the polymerase chain reaction.  Eur J Clin Microbiol Infect Dis. 1999;  18 716-722
  CrossrefPubMedGoogle Scholar
• 27 Lindsay D S, Abraham W H, Fallon R J. Detection of mip geneby PCR in diagnosis of Legionnaires' disease.  J Clin Microbiol. 1994;  32 3068-3069
  PubMedGoogle Scholar
• 28 Hayden R T, Uhl J R, Qian X, Hopkins M K, Aubry M C, Limper A H, Lloyd R V, Cockerill F R. Direct detection of Legionella species from bronchoalevolar lavage and open lung biopsy specimens: comparison fo LightCycler PCR, in situ hybridisation, direct fluorescence antigen detection, and culture.  J Clin Microbiol. 2001;  39 2618-2626
  CrossrefPubMedGoogle Scholar
• 29 Schaberg T, Dalhoff K, Ewig S, Lorenz J, Wilkens H. Deutsche Gesellschaft für Pneumologie. Empfehlungen zur Therapie der ambulant erworbenen Pneumonie.  Pneumologie. 1998;  52 450-462
  PubMedGoogle Scholar
• 30 Bartlett J G, Dowell S F, Mandell L A, File T M, Musher D M, Fine M J. Practice guidelines for the management of community-acquired pneumonia in adults.  Clin Infect Dis. 2000;  31 347-382
  CrossrefPubMedGoogle Scholar
• 31 Mandell L A, Marrie T J, Grossman R F, Chow A W, Hyland R H. and the Canadian Community-acuired working group . Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society.  Clin Infect Dis. 2000;  31 383-421
  CrossrefPubMedGoogle Scholar
• 32 Fraser D W, Tsai T R, Orenstein W, Parkin W E, Beecham H J, Sharrar R G, Harris J, Mallison G F, Martin S M, McDade J E, Shepard C C, Brachman P S. Legionnaires' disease: description of an epidemic of pneumonia.  N Engl J Med. 1977;  297 1189-1197
  CrossrefPubMedGoogle Scholar
• 33 Edelstein P H. Antimicrobial chemotherapy for Legionnaires' disease: a review.  Clin Infect Dis. 1995;  21 (Suppl 3) 265-276
  PubMedGoogle Scholar
• 34 Johnson D M, Erwin E, Barrett M S, Gooding B B, Jones R N. Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species.  Eur J Clin Microbiol Infect Dis. 1992;  11 751-755
  PubMedGoogle Scholar
• 35 Nimmo G R, Bull J Z. Comparative susceptibility of Legionella pneumophila and Legionella longbeachae to 12 antimicrobial agents.  J Antimicrob Chemother. 1995;  36 219-223
  PubMedGoogle Scholar
• 36 Reda C, Quaresima T, Pastons M C. In vitro activity of six intracellular antibiotics against Legionella pneumophila strains of human and experimental origin.  J Antimicrob Chemother. 1994;  33 757-764
  PubMedGoogle Scholar
• 37 Baltch A L, Smith R P, Franke M A, Michelsen P B. Antibacterial effects of Levofloxacin, Erythromycin and Rifampin in a human moncyte system against Legionella pneumphila.  Antimicrob Agents and Chemother. 1998;  42 3153-3156
  PubMedGoogle Scholar
• 38 Stout J E, Arnold B, Yu V I. Activity of azithromycin, clarithromycin, roxithromycin, dirithromycin, quinupristin/dalfopristin and erythromycin against Legionella species by intracellular suspectibility testing in HL-60 cells.  J Antimicrob Chemother. 1998;  41 289-291
  CrossrefPubMedGoogle Scholar
• 39 Fitzgeorge R B, Lever S, Baskerville A. A comparison of th efficacy of azithromycin and clarithromycin in oral therapy of experimental airborne Legionnaires' disease.  J Antimicrob Chemother. 1993;  31 Suppl E 171-176
  PubMedGoogle Scholar
• 40 Edelstein P H, Edelstein M AC. In vitro activity of azithromycin against clinical isolates of Legionella species.  Antimicrob Agents Chemother. 1991;  35 180-181
  PubMedGoogle Scholar
• 41 Hamedani P, Ali J, Hafeez S, Bachand Jr R, Dawood G, Quereshi S, Raza R, Yab Z. The safety and efficacy of clarithromycin in patients with Legionella pneumonia.  Chest. 1991;  100 1503-1506
  PubMedGoogle Scholar
• 42 Vergis E N, Indorf A, File T M, Phillips J, Bates J, Tan J, Sarosi G A, Grayston T, Summersgill J, Yu V L. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients.  Arch Intern Med. 2000;  160 1294-1300
  CrossrefPubMedGoogle Scholar
• 43 Plouffe J, Schwartz D B, Kolokathis A, Sherman B W, Arnow P M, Gezon J A, Suh D, Anzueto A, Greenberg R N, Niederman M, Paladino J A, Ramirez J A, Inverso J, Knirsch C A. and the azithromycin intravenous clinical trials group . Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia.  Antimicrob Agents Chemother. 2000;  44 1796-1802
  CrossrefPubMedGoogle Scholar
• 44 Myburgh J, Nagel G J, Petschel E. The efficacy and tolerance of a three-day course of azithromycin in the treatment of community-acquired pneumonia.  J Antimicrob Chemother. 1993;  31 (Suppl E) 163-169
  PubMedGoogle Scholar
• 45 Kuzmann I, Soldo I, Schonwald S, Culig J. Azithromycin for treatment of community-acquired pneumonia caused by Legionella pneumophila: a retrospective study.  Scand J Infect Dis. 1995;  27 503-505
  PubMedGoogle Scholar
• 46 Matute A J, Schurink C AM, Hoepelman I M. Is a 5-day course of azithromycin enough for infections caused by Legionella pneumophila?.  J Antimicrob Chemother. 2000;  45 919-931
  CrossrefPubMedGoogle Scholar
• 47 Reda C, Quaresima T, Pastoris M C. In vitro activity of six intracellular antibiotics against Legionella pneumophila strains of human and environmental origin.  J Antimicrob Chemother. 1994;  33 757-764
  PubMedGoogle Scholar
• 48 Schülin T, Wennerstein C B, Ferraro M J, Moellering Jr R C, Eliopoulos G M. Susceptibilities of Legionella spp. to newer antimicrobials in vitro.  Antimicrob Agents Chemother. 1998;  42 1520-1523
  PubMedGoogle Scholar
• 49 Edelstein P H, Edelstein M A, Lehr K H, Ren J. In-vitro activity of levofloxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumphila pneumonia.  J Antimicrob Chemother. 1996;  37 117-126
  CrossrefPubMedGoogle Scholar
• 50 Jonas D, Engels I, Friedhoff C, Spitzmüller B, Daschner F D, Frank U. Efficacy of moxifloxacin, trovafloxacin, clinafloxacin and levofloxacin against intracellular Legionella pneumophila.  J Antimicrob Chemother. 2001;  47 147-152
  CrossrefPubMedGoogle Scholar
• 51 Doumon E, Mayaud C, Wolff M, Sclemmer B, Samuel D, Sollet J P. et al . Comparison of the activity of three antibiotic regimens in severe Legionnaires' disease.  J Antimicrob Chemother. 1990;  26 Suppl B 129-139
  PubMedGoogle Scholar
• 52 File Jr T M, Segreti J, Dunbar L, Player R, Kohler R, Williams R R, Kojak C, Rubin A. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.  Antimicrob Agents Chemother. 1997;  41 1965-1972
  PubMedGoogle Scholar
• 53 Edelstein P H, Shinzato T, Edelstein M AC. BMS-284756 (T-3811 ME) a new fluoroquinolone: in vitro activity against Legionella. Efficacy in a guinea pig meodel of L. pneumophila pneumonia and pharmacokinetics in guinea pigs.  J Antimicrob Chemother. 2001;  48 667-675
  CrossrefPubMedGoogle Scholar
• 54 Nowicki M, Paucod J C, Bornstein N, Meugnier H, Isoard P, Fleurette J. Comparative efficacy of five antibiotics on experimental airborne Igionellosis in guinea-pigs.  J Antimicrob Agents. 1988;  22 513-519
  PubMedGoogle Scholar
• 55 Barker J E, Farrel I D. The effects of single and combined antibiotics on the growth of Legionella pneumophila using time-kill studies.  J Antimicrob Chemother. 1990;  26 45-53
  PubMedGoogle Scholar
• 56 Edelstein P H, Edelstein M AC. In vitro activity of the Ketolide HMR 3647 (RU 6647) for legionella spp., its pharmacokinetics in guinea pigs, and the use of the drug to treat guinea pigs with legionella pneumophila pneumonia.  Antimicrob Agents and Chemother. 1999;  43 90-95
  PubMedGoogle Scholar
• 57 Leroy B, Rangaraju M. Efficacy of telithromycin (HMR 3647), a new once-daily ketolide, in community-acquired pneumonia caused by atypical pathogens. ICAAC Toronto 2000: Abstract 2225
  Google Scholar
• 58 Bebear C, Bouanchaud D H. A review of the in-vitro activity of quinopristin/dalfopristin against intracellular pathogens and mycoplasmas.  J Antimicrob Chemother. 1997;  39 Suppl A 59-62
  CrossrefPubMedGoogle Scholar
• 59 Edelstein P H, Edelstein M A. In vitro activity of quinopristin/dalfoprostin (Synercid, RP 59500) against Legionella spp.  Diagn Microbiol Infect Dis. 2000;  36 49-52
  CrossrefPubMedGoogle Scholar
• 60 Hubbard R B, Mathur R M, Macfarlane J T. Severe community-accquired legionella pneumonia: treatment, complications, and outcome.  Quart J Med. 1993;  86 327-332
  PubMedGoogle Scholar
• 61 Dedicoat M, Venkatesan P. The treatment of legionaires' disease.  J Antimicrob Chemother. 1999;  43 747-752
  CrossrefPubMedGoogle Scholar
• 62 Edelstein P H. Antimicrobial chemotherapy for Legionnaires disease: time for a change.  Ann Intern Med. 1998;  129 328-330
  PubMedGoogle Scholar

Priv.-Doz. Dr. med. S. Ewig

Medizinische Universitäts-Poliklinik Bonn

Wilhelmstraße 35

53111 Bonn

Email: santiago.ewig@ukb.uni-bonn.de